Stocks in play: Marvel Biosciences Corp

Announces that it has successfully completed a multi-kilogram scale run under current good manufacturing practices of the active pharmaceutical ingredient of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd.. The cGMP material obtained from this study will be utilized in the Company's upcoming Phase 1 clinical study. MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. Marvel Biosciences Corp shares V.MRVL are trading unchanged at $0.12.

Read:

• Addressing the USA’s 200 to 1 Security Protection Gap is a Serious Concern for Tech Companies

• Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

• Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

• Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

• New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates